Applications

1691 – PromarkerD testing in patients with type 2 diabetes to determine the risk of developing diabetic kidney disease

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation Closed
  • Pre-MSAC consultation Closed
  • Outcome Not supported

Application details

Reason for application

New MBS item.

Service or technology in this application

PromarkerD is a blood test designed to predict the risk of developing diabetic kidney disease (DKD) or progression of DKD in patients with type-2 diabetes (T2D).The test measures three plasma protein biomarkers (ApoA4, CD5L and IBP3) which are found in the blood, combined with clinical factors (age, HDL-cholesterol, kidney function) to generate prognostic risk scores for DKD in patients with T2D. The concentrations of the biomarkers, along with the clinical factors, are entered into the PromarkerD Hub, a static proprietary software algorithm which characterises patients as low-risk, moderate-risk, or high-risk of developing DKD.

Type: Investigative technology

Medical condition this application addresses

Diabetic Kidney Disease (DKD) is a type of kidney disease caused in patients with diabetes. The kidneys are the body’s filtration system, removing waste and extra water from the blood. They also produce hormones and help to control blood pressure. When the kidneys are damaged, they no longer function effectively causing waste to build up leading to a range of health problems.

Consultation survey and deadlines

  • PASC consultation: Closed
  • MSAC consultation: Closed Friday 7 October 2022

Meetings to consider this application

  • PASC meeting: 9–10 December 2021
  • ESC meeting: 6–7 October 2022
  • MSAC meeting: 24–25 November 2022